Many of today’s treatments require trade-offs in efficacy, safety, and convenience. Eupraxia’s founders started the company believing the norm in medical interventions isn’t good enough; people deserve better.
Eupraxia’s proprietary Diffusphere™ technology is a potential breakthrough in extended-release, site-specific drug delivery. Diffusphere is engineered to improve treatment outcomes, reduce systemic side effects, and simplify patient care.
Eupraxia’s clinical pipeline is patient-centric, addressing high-need, underserved indications in gastrointestinal and musculoskeletal diseases. Our clinical programs reflect the versatility and promise of our Diffusphere technology beyond our current focus on eosinophilic esophagitis (EoE) and joint pain. The goal is to expand Diffusphere across more therapeutic areas – through partnerships, licensing, and collaborative research – where localized, extended-release drug delivery can potentially drive meaningful improvements in treatment efficacy and patient experience.
Eupraxia’s culture fosters ingenuity, passion, and the freedom to explore, with a leadership team that combines deep expertise in formulation design and development, clinical studies, regulatory strategy, and commercial planning. Our rigorous approach to research and development and commitment to scientific excellence means good enough will never be good enough.
Rethinking the norm, revolutionizing targeted therapies and drug delivery, redefining relief, and restoring quality of life. It’s beyond innovation; it’s Eupraxia.
We communicate openly, comprehensively, and proactively. We believe that effective communication means making complex ideas clear, concise, and compelling, ensuring that everyone fully understands and aligns with our goals. We value simplicity, honesty, and straightforwardness to foster trust and drive action.
We challenge ourselves and each other to be responsible, accountable, and inclusive. We believe a flatter, more open organization empowers us to be more effective and agile. By building an environment of respect and support, we create a place where everyone’s contributions are valued, and we enjoy working together.
We foster an environment that champions ingenuity, curiosity, and the freedom to create original solutions. We encourage bold, passionate thinking to drive the future of Eupraxia.
We are results-driven and accountable, focusing on clear goals and positive outcomes. We approach our work with urgency, efficiency, and a commitment to improving patients' lives.
We take the initiative, consistently seeking opportunities and solutions that benefit our team and our vision. We don’t just respond; we lead by anticipating and acting on emerging needs and possibilities.
Eupraxia Pharmaceuticals is a clinical-stage biotechnology company focused on developing locally delivered, extended-release therapeutics designed to improve treatment outcomes and patient quality of life.
Eupraxia is a clinical-stage biotechnology company developing targeted therapies that leverage a proprietary extended-release delivery system to provide the right dose of a drug in the right place for the right amount of time.
Eupraxia Pharmaceuticals
201-2067 Cadboro Bay Rd.
Victoria BC, Canada, V8R 5G4
